Recombinant Human Wnt/RSPO1 Agonist Protein, CF

Catalog #: BT-WRSP1 Datasheet / COA / SDS

Improve your stem cell and organoid cultures with our New Wnt/R-Spondin Agonist Proteins (Catalog # BT-WRSP1, # BT-WRSP2, and # BT-WRSP3). These proteins exhibit similar or higher activity than the individual Wnt-3a and R-Spondin proteins together, simplifying experiments and providing time and cost savings. See the data in this Application Note.

Catalog #	Availability	Size / Price	Qty
BT-WRSP1-050
BT-WRSP1-100
BT-WRSP1-500
BT-WRSP1-01M

Recombinant Human Wnt/RSPO1 Agonist Protein Bioactivity.

2 Images

Product Details

Reviews

Summary Product Datasheets Carrier Free Data Images Reconstitution Calculator Background Related Research Areas

Recombinant Human Wnt/RSPO1 Agonist Protein, CF Summary

R&D Systems CHO-derived Recombinant Human Wnt/RSPO1 Agonist Protein (BT-WRSP1)
Quality control testing to verify active proteins with lot specific assays by in-house scientists
All R&D Systems proteins are covered with a 100% guarantee

Product Specifications

Endotoxin Level

<0.10 EU per 1 μg of the protein by the LAL method.

Activity

Measured by its ability to activate TCF reporter activity in HEK293 human embryonic kidney cells. The ED₅₀ for this effect is 7.00‑84.0 ng/mL.

Source

Chinese Hamster Ovary cell line, CHO-derived human Wnt/RSPO1 protein
Proprietary

Structure / Form

Disulfide-linked homodimer

SDS-PAGE

86-96 kDa and >190 kDa, under reducing conditions.

Product Datasheets

BT-WRSP1

Product Datasheet

COA

SDS

Carrier Free

What does CF mean?

CF stands for Carrier Free (CF). We typically add Bovine Serum Albumin (BSA) as a carrier protein to our recombinant proteins. Adding a carrier protein enhances protein stability, increases shelf-life, and allows the recombinant protein to be stored at a more dilute concentration. The carrier free version does not contain BSA.

What formulation is right for me?

In general, we advise purchasing the recombinant protein with BSA for use in cell or tissue culture, or as an ELISA standard. In contrast, the carrier free protein is recommended for applications, in which the presence of BSA could interfere.

BT-WRSP1

Formulation	Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose.
Reconstitution	Reconstitute at 500 μg/mL in PBS.
Shipping	The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage:	Use a manual defrost freezer and avoid repeated freeze-thaw cycles. 12 months from date of receipt, -20 to -70 °C as supplied. 1 month, 2 to 8 °C under sterile conditions after reconstitution. 3 months, -20 to -70 °C under sterile conditions after reconstitution.

Scientific Data

Bioactivity

View Larger

Recombinant Human Wnt/RSPO1 Agonist (Catalog # BT-WRSP1) activates TCF reporter activity in HEK293 human embryonic kidney cells. The ED₅₀ for this effect is 7.00-84.0 ng/mL.

SDS-PAGE

View Larger

2 μg/lane of Recombinant Human Wnt/RSPO1 Agonist Protein (Catalog # BT-WRSP1) was resolved with SDS-PAGE under reducing (R) and non-reducing (NR) conditions and visualized by Coomassie® Blue staining, showing bands at 86-96 & >190 kDa under reducing conditions.

Reconstitution Calculator

Background: Wnt/RSPO1

Wnt signaling is known to promote self-renewal of adult stem cells. R-Spondins amplify Wnt signaling in adult stem cells by binding to LGR5 receptors resulting in increased levels of Wnt receptor localization at the membrane surface. Many current organoid protocols include addition of Wnt-3a and R-Spondin proteins to the media for optimal adult stem cell maintenance and health of organoids. Fusion proteins known as Wnt Surrogates have been described that have enhanced solubility when compared to the widely used Wnt-3a protein and mirror the activities of Wnt signaling.¹ R&D Systems has constructed recombinant fusion proteins designed to bind elements of the Wnt receptor system including LGR-5, Frizzled, and LRP-5/6. These can initiate canonical Wnt signaling and are designed to simplify cell culture protocols by substituting for conditioned media or the addition of recombinant Wnt and R-Spondin.

References